Paloma Partners’s SELLAS Life Sciences SLS Stock Holding History

Paloma Partners’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-81	Closed	-$70K	–	2398
2017 Q2	$70K	Buy	+81	New	+$70.5K	﹤0.01%	2098

Other funds holding SLS

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Paloma Partners's SLS Position: Q3 2017 in Review

Paloma Partners sold out of SELLAS Life Sciences (SLS) in Q3 2017, closing a stake of 81 shares — an estimated $70K sold.

Paloma Partners first reported a position in SLS in Q2 2017 and held it in 1 quarter. The position peaked at $70K in Q2 2017. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2017.

Paloma Partners reported no remaining SELLAS Life Sciences position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 81 SELLAS Life Sciences shares in Q3 2017, an estimated $70K.
Paloma Partners first reported a position in SELLAS Life Sciences in Q2 2017 and held it in 1 quarter.
Paloma Partners's SELLAS Life Sciences position peaked at $70K in Q2 2017.
28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.